Fig. 7.

Schematic of MUC17 inhibits the progression of human gastric cancer by limiting inflammatory responses. Inflammatory factors induce the expression of MUC17 through upregulating CDX1. MUC17 is dependent on its conserved epidermal growth factor domain and on downstream sequences to enable its interaction with myosin-9, resulting in a sustained regulatory feedback loop between myosin-9, p53, and RhoA, and then activation of p38 to negatively regulate the NFκB pathway in GC cells. Inflammatory factor promotes cancer cell growth through activating NFκB pathway, hence, MUC17 can limiting inflammatory responses